<DOC>
	<DOCNO>NCT00996515</DOCNO>
	<brief_summary>PRIMARY OBJECTIVES : I . To document toxicity , reversibility toxicity , regimen 5-azacytidine ( azacitidine ) erlotinib ( erlotinib hydrochloride ) . SECONDARY OBJECTIVES : I . To determine potential anti-tumor effect , determine objective tumor response ( complete partial response ) , clinical benefit ( complete partial response , clinical benefit ) , time tumor response , time tumor progression , overall survival .</brief_summary>
	<brief_title>A Phase 1 Protocol 5-Azacytidine Erlotinib Advanced Solid Tumor Malignancies</brief_title>
	<detailed_description>OUTLINE : This dose-escalation study . Patients receive azacitidine intravenously ( IV ) 10-40 minute subcutaneously ( SC ) day 1 15 , day 1-2 15-16 , day 1-3 15-17 , day 1-4 15-18 . Patients also receive erlotinib hydrochloride orally ( PO ) daily day 1-21 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 28 day every 3 month 5 year .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patients must fulfill follow criterion eligible study entry : Those eligible patient nonhematologic neoplasm ( lymphoma , leukemia , myeloma , myelodysplasia , myeloproliferative syndrome ) disease previously treat and/or acceptable standard treatment regimen available , treat definitively either surgery radiotherapy . All appropriate candidate treatment , candidate treatment protocols high priority . All patient ECOG/Zubrod/SWOG performance status &lt; 2 time initiation therapy , adequate endorgan function , severe comorbid disease , ability provide inform consent . Other Eligibility Criteria : Signed Informed Consent ECOG/Zubrod/SWOG Performance Status &lt; 2 ( Karnofsky Performance Status &gt; 70 % ) Life expectancy &gt; 8 week Male female ' age &gt; 18 year Patients childbearing potential must use effective mean contraception . Women childbearing potential must negative serum pregnancy test prior azacitidine treatment . Histologic diagnosis solid tumor malignancy advance treat adequately radiotherapy surgery ; metastatic disease Baseline laboratory value ( bone marrow , renal , hepatic ) : Adequate bone marrow function : Absolute neutrophil count &gt; 1000/µL Platelet count &gt; 100'000/µL Renal function : Serum creatinine &lt; 1.5 x ULN Hepatic function : Bilirubin &lt; 1.5x normal Serum glutamicoxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) serum glutamicpyruvic transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) level &lt; =2 x ULN Serum calcium &lt; 12 mg/dl Patients meet follow criterion ineligible study entry : Pregnant lactating female Myocardial infarction ischemia within 6 month Cycle 0 ' Day 0 Uncontrolled ' clinically significant dysrhythmia Prior radiotherapy indicator lesion unless objective evidence tumor growth lesion Uncontrolled metastatic disease central nervous system Sensitivity erlotinib , 5azacytidine mannitol Advanced hepatic tumor Radiotherapy within 2 week Cycle 1 ' Day 1 Surgery within 2 week Cycle 1 ' Day 1 Any co morbid condition ' view attend physician ' render patient high risk treatment complication</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Advanced Solid Tumor Malignancies</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Vidaza</keyword>
	<keyword>Tarceva</keyword>
	<keyword>5-azacytidine</keyword>
</DOC>